Overview of Ibogaine Treatment
Ibogaine, a naturally occurring psychoactive compound derived from the root bark of the Tabernanthe iboga, has garnered attention for its potential in treating addiction, particularly opioid use disorder. The substance promotes profound psychological experiences and is often administered in high doses, sometimes referred to as ‘flood doses’ [3]. Such doses aim to assist individuals in overcoming substance dependence, although they are usually administered in unregulated environments lacking rigorous medical oversight.
Psychedelic therapies, including ibogaine, are becoming topics of both public and scientific interest as researchers investigate their safety, efficacy, and potential to facilitate therapeutic breakthroughs in addiction recovery [4]. Gerber's experience with ibogaine has brought further attention to the practice, serving as a case study in the intersection of celebrity culture and alternative medicine.
Gerber's Experience with Ibogaine
On or around March 26, 2026, Presley Gerber posted a video and accompanying text on Instagram documenting his preparations for receiving an ibogaine flood dose at a wellness facility in Cancún [5]. In his message, he shared a moment of reflection, stating, “Quiet moment before everything changed,” and expressed feelings of fear regarding the treatment process [6].
Gerber’s statements indicated an understanding of this intervention as part of his journey toward confronting issues related to his addiction, which included references to a near-fatal fentanyl overdose earlier in his life. He commented on the challenge of surrendering control during the treatment, a sentiment echoed by many undergoing similar treatment modalities [7].
Pharmacological Mechanism of Ibogaine
Ibogaine acts on numerous neurotransmitter systems, which may contribute to its therapeutic effects on addiction. The compound is metabolized into noribogaine, a metabolite that maintains pharmacological activity and plays a significant role in the treatment process [8]. Research indicates that ibogaine interacts with opioid, serotonin, and dopamine receptors, although the specific pathways through which it alleviates withdrawal symptoms and cravings are not fully understood [9].
Moreover, the delayed effects of ibogaine and noribogaine can persist long after the acute psychedelic experience, leading to complex implications for treatment duration and expectations [10]. The unique pharmacodynamics of ibogaine bring forth considerations about the precision of dosing and the necessity of medical supervision during treatment.
Clinical Evidence and Findings
Research on ibogaine has produced mixed results. Observational studies suggest that ibogaine can reduce withdrawal symptoms and cravings in individuals with opioid dependence . A prominent study by Mash et al. (2001) focused on the detoxification effects of ibogaine, reporting favorable outcomes, though with a limited sample size and short follow-up duration .
Additionally, randomized controlled trials, while scarce, remain crucial for establishing more robust conclusions regarding ibogaine's efficacy. Studies indicate that while some patients experience profound psychological transformations, many factors—such as concurrent therapeutic interventions and genetics—may significantly influence outcomes .
Risks and Cardiac Safety Concerns
One of the most pressing safety concerns associated with ibogaine treatment is its impact on cardiac function. Ibogaine has been shown to inhibit cardiac ion channels, particularly the hERG potassium channel, potentially leading to QT interval prolongation and increased risk of torsades de pointes, a lethal arrhythmia . Given Gerber's history of recent opioid use and overdose, these risks become especially salient as reduced opioid tolerance heightens the danger during relapse after treatment.
Furthermore, the implications of polysubstance use are particularly concerning within the context of ibogaine therapy. Users may not fully disclose other substances consumed prior to treatment, which exacerbates risks associated with cardiac events and overdose . Comprehensive screening including ECG and electrolyte assessments is critical, yet often lacking in many treatment settings.
Ibogaine Treatment Protocols
Treatment protocols for ibogaine administration can vary widely. In settings that prioritize safety, protocols may include comprehensive pre-screening, individualized dosing based on body weight and psychological profile, and robust post-treatment care systems . While Gerber’s treatment cannot be classified under structured medical supervision based on the publicly available information, optimal care involves a monitored environment to address acute reactions and clinical follow-up to support recovery .
The rationale for an ibogaine flood dose typically includes an extensive duration of drug effects, allowing for profound psychological processing. However, the absence of standardized dosing regimens can pose a hazard. No data in Gerber’s description provide insight into whether any medical assessments or support were conducted alongside his treatment experience .
Legal Status of Ibogaine by Jurisdiction
The legal status of ibogaine varies significantly across jurisdictions. In the United States, ibogaine remains a Schedule I controlled substance, rendering its use in clinical settings illegal . Conversely, countries such as Mexico and Costa Rica provide avenues for ibogaine therapy in less regulated environments, often marketing themselves as retreat centers .
This legal ambiguity fosters a complex landscape where individuals, like Gerber, may seek treatment abroad, despite potential risks inherent in unregulated settings. As interest in psychedelic compounds for therapeutic purposes grows, advocacy for re-evaluating ibogaine's legal status continues to gain traction within both the medical community and the public .
Death of Presley Gerber
Presley Gerber died on September 20, 2026, at the age of 27 while staying at a rehabilitation facility in Santa Monica, California. His death was confirmed by his family representative and the Los Angeles County Medical Examiner. Gerber had entered the facility shortly before his death as he continued to seek treatment for substance use and addiction.
The Santa Monica Police Department is investigating Gerber’s death as a suspected drug overdose and has stated that there is currently no indication of foul play. An autopsy was performed, but the Los Angeles County Medical Examiner deferred determination of the official cause and manner of death pending additional testing, including toxicology results.
Gerber's death came approximately six months after he publicly documented undergoing an ibogaine flood dose in Cancún, Mexico. In March 2026, he shared his preparations for the treatment on Instagram and discussed his fear, addiction struggles, and hope that the experience would help him regain control of his life.
There is currently no established evidence that Gerber's earlier ibogaine treatment caused or contributed to his death. The treatment and his death were separated by several months, and authorities have not publicly connected ibogaine to the circumstances of his death. His experience nevertheless became part of the wider public discussion surrounding ibogaine because he was one of the more prominent individuals to openly document receiving the treatment for substance-use problems shortly before his death.
Future Outlook and Developments
Looking ahead, the field of psychedelic therapy is poised for rapid evolution, particularly with ongoing research initiatives focused on compounds like ibogaine. As of 2023, an increasing number of clinical trials are underway to assess the safety and efficacy of ibogaine as a potential treatment for opioid dependence . Additionally, as public interest swells, discussions surrounding the integration of psilocybin and ayahuasca into mainstream medicine may overlap with those concerning ibogaine, drawing attention to comparative efficacy and safety profiles .
The future of substances like ibogaine will depend significantly on substantiated evidence from clinical studies, which could potentially lead to shifts in legal frameworks and increased acceptance within conventional medical practice. Efforts to synthesize and regulate compounds such as ibogaine may emerge as global discourse on psychedelic therapy evolves and transitions toward evidence-based applications .